TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01959490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03463616

Intervention type: RADIATION
Intervention: CT abdomen
Description: CT scan of abdomen for metastasis staging of rectal cancer
Study: NCT01959490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03691688

Intervention type: DRUG
Intervention: Aspirin 100 mg
Description: Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion

Intervention type: DRUG
Intervention: Clopidogrel 75mg
Description: Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
Study: NCT01834898

Intervention type: DRUG
Intervention: Controlled-release oxycodone
Description: Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
Study: NCT06136897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT05589025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy technique with formocresol
Description: The pulpotomy procedure performed was a modification of that described by Pinkham et al; 2005 where pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. After the completion of the access cavity, coronal pulp was extirpated using a sharp excavator. Any residual coronal pulpal tissue was removed using a sterile round bur in a slow-speed handpiece to a depth of few millimeters below the free gingival margin. Hemostasis was achieved with a water-dampened cotton pellet. If hemostasis was not achieved after the initial application of the cotton pellet, the case was eliminated from the study. Following hemostasis, a cotton pellet, moistened with formocresol was applied for 3 minutes and removed. A zinc- oxide and eugenol base was placed over the amputation site. Thereafter, a glass ionomer base was applied.
Study: NCT03610789

Intervention type: DEVICE
Intervention: REDAPT
Description: REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
Study: NCT03463616

Intervention type: RADIATION
Intervention: MRI abdomen
Description: MRI of abdomen for metastasis staging of rectal cancer
Study: NCT05589025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpectomy technique with zinc oxide and eugenol
Description: The pulpectomy procedure used herein was a modification of that described by Payne et al;1993 Pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. An initial endodontic K-file fitting snugly in the canal was introduced inside it. In most cases, the pulp tissue was removed completely on the first attempt. If the first attempt was unsuccessful, the procedure was repeated and canals were generally enlarged three sizes past the initial file to eliminate the organic remnants. Copious irrigation with a light flow of sterile 0.9% NaCl-solution was used throughout the procedure. At the end, the canals were dried and filled with zinc-oxide \& eugenol.
Study: NCT03278522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
Study: NCT02023866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate
Description: Cysteamine Bitartrate Delayed-release capsules
Study: NCT01142570

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Support (Group 1)
Description: Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Support (Group 2)
Description: For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein dose of 1.1 to 1.5 grams per kilogram weight.
Description: Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein at 1.1 grams per kilogram weight.
Description: Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein at a dose of 1.5 grams per kilogram weight.
Description: Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
Study: NCT04234815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CETA Short Session (CSS)
Description: CETA Short Session (CSS) is a brief, low-intensity psychosocial intervention incorporating foundational components of the Common Elements Treatment Approach (CETA). CETA is an 8-12 session, transdiagnostic psychotherapy for common mental disorders. CSS was designed to serve as both a prevention/support approach for a broader range of needs, as well as an engagement/outreach strategy to identify and refer individuals to treatment. CSS is delivered in a group format over approximately two hours and consists of: 1) Psychoeducation: instruction about the brain and brain functioning, including normalization of psychological responses to stress and a brief self-assessment; 2) Safety: screening and referral for individuals identified as at risk of harm to self or others; and 3) Cognitive coping: based on the cognitive triangle, participants practice identifying an unhelpful thought changing it to a more helpful alternative, and examining how these thoughts impact feelings and behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and Safety
Description: This intervention is the same as CSS with the exception that the cognitive coping skill training is removed.
Study: NCT03084575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy
Description: Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)
Description: L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal RF lesioning is done using Bailys RF generator
Study: NCT00718419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression.
Study: NCT00861367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transurethral surgery with or without aspirin
Description: aspirin 100mg once a day, transurethral surgery with or without aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: transurethral surgery with or without aspirin
Description: aspirin 100mg once a day, transurethral surgery with or without aspirin
Study: NCT06365294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue extracranial stenting
Description: Rescue extracranial stenting in tandem occlusions
Study: NCT02397213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
Study: NCT01523119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Orally Disintegrating Tablets 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Orally Disintegrating Tablets 8 mg
Study: NCT01902082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04119726

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Text Messages
Description: Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Text Messages
Description: Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized reminders
Description: Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based counselling
Description: The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database
Study: NCT02676076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 100/6/12.5 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 100/6 µg
Study: NCT02361203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
Study: NCT01453153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: (Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: (Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
Study: NCT05247931

Intervention type: DIAGNOSTIC_TEST
Intervention: TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine
Description: Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2

Intervention type: DIAGNOSTIC_TEST
Intervention: TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine
Description: Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
Study: NCT00363805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03653611

Intervention type: OTHER
Intervention: On-site Practice Assessment
Description: The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
Study: NCT02821169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
Study: NCT01291004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day levonorgestrel oral contraceptive
Description: Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
Study: NCT02981186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of hydrophobic material
Study: NCT02821169

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution 0.9%
Description: injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
Study: NCT01895062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Management System (AMS)
Description: The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway.
Study: NCT02981186

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation comparator
Description: Implantation of trifocal IOL POD F consisting of hydrophilic material
Study: NCT02054299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Amitriptyline
Description: Amitriptyline: 25 mg, single oral application
Study: NCT02021578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Cognitive Behavioral Prevention
Description: Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
Study: NCT02054299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Desvenlafaxine
Description: Desvenlafaxine: 50 mg, single oral application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Sumatriptan
Description: Sumatriptan: 50 mg, single oral application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Proguanil
Description: Proguanil: 200mg, single oral application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Fenoterol
Description: Fenoterol: 180 mcg, single intravenous application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug application Thiamine
Description: Thiamine: 200mg, single oral application
Study: NCT00828672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered on days 15,22,29,36 en 43; 50 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered on days 1,15,29 and 43 ; 5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered on days 1,15,29 and 43 ; 5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Total dose 45Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Total dose 45Gy
Study: NCT03901729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1753011
Description: Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1753011
Description: Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1753011
Description: Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo BAY 1753011
Description: Tablet; Once daily in the morning; Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BAY 1753011
Description: Tablet; Once daily in the morning; Oral

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo BAY 1753011
Description: Tablet; Once daily in the morning; Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Tablet; 40mg unit; 80mg once daily in the morning; Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Tablet; 40mg unit; 80mg once daily in the morning; Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Furosemide
Description: Tablet; Once daily in the morning; Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Furosemide
Description: Tablet; Once daily in the morning; Oral
Study: NCT00641381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 100 mg/kg on day -2 prior to stem cell reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg on day -4 prior to stem cell reinfusion
Study: NCT02021578

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written information
Description: Reading materials about depression
Study: NCT00641381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Reinfusion of autologous stem cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Reinfusion of autologous stem cells
Study: NCT01006746

Intervention type: OTHER
Intervention: Remote monitoring by Home Monitoring system
Description: Standard of care completed with remote monitoring for ICD patients follow-up
Study: NCT04180267

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-magnitude High-frequency Vibration
Description: 35Hz, 0.3g, 20min/day, at least 3 times/week
Study: NCT01105884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biatin Ag (Foam)
Description: All the subjects will be treated with Biatin Ag (Foam)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocolloid
Description: All the subjects in this group will be treated with Hydrocolloid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: All the subjects in this group will be treated with Hydrogel